Jasper Therapeutics Inc
JSPR1.950USD
+0.140+7.73%
收盤 11/05, 16:00（美東）報價延遲15分鐘
31.63M總市值
虧損本益比TTM
關於 Jasper Therapeutics Inc 公司
Jasper Therapeutics, Inc. 是一家臨牀階段的生物技術公司。該公司專注於開發針對肥大細胞驅動疾病的療法，例如慢性自發性蕁麻疹 (CSU) 和慢性誘發性蕁麻疹 (CIndU)。該公司還在針對患病造血幹細胞可以帶來益處的疾病開展項目，例如低風險至中等風險骨髓增生異常綜合徵 (LR-MDS) 和幹細胞移植調理方案。該公司的主要候選產品 briquilimab 是一種單克隆抗體，旨在阻止幹細胞因子 (SCF) 與肥大細胞和幹細胞上的 CD117 (c-Kit) 受體結合並通過該受體發出信號。SCF/c-Kit 通路是肥大細胞的生存信號。該公司還在開發 briquilimab 作爲一次性調理療法，用於接受第二次幹細胞移植的嚴重聯合免疫缺陷 (SCID) 患者，該公司正在爲此進行 1/2 期臨牀試驗。
Jasper Therapeutics Inc簡介
公司代碼JSPR
公司名稱Jasper Therapeutics Inc
上市日期Nov 20, 2019
CEOMr. Ronald A. (Ron) Martell
員工數量64
證券類型Ordinary Share
年結日Nov 20
公司地址2200 Bridge Pkwy Suite #102
城市REDWOOD CITY
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94065
電話16505491400
網址https://jaspertx.com/
公司代碼JSPR
上市日期Nov 20, 2019
CEOMr. Ronald A. (Ron) Martell
Jasper Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Ronald A. (Ron) Martell
Mr. Ronald A. (Ron) Martell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
74.12K
+123.80%
Mr. Jeetinder Singh (Jeet) Mahal
Mr. Jeetinder Singh (Jeet) Mahal
Chief Operating Officer
Chief Operating Officer
25.37K
+1.44%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Thomas G. (Tom) Wiggans
Mr. Thomas G. (Tom) Wiggans
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
4.73K
-5.40%
Mr. Vishal Kapoor
Mr. Vishal Kapoor
Independent Director
Independent Director
4.38K
--
Dr. Judith Shizuru, M.D., Ph.D.
Dr. Judith Shizuru, M.D., Ph.D.
Director
Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Kurt Von Emster
Mr. Kurt Von Emster
Independent Director
Independent Director
--
--
Mr. Christian W. Nolet
Mr. Christian W. Nolet
Independent Director
Independent Director
--
--
Mr. Herb Cross
Mr. Herb Cross
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Ronald A. (Ron) Martell
Mr. Ronald A. (Ron) Martell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
74.12K
+123.80%
Mr. Jeetinder Singh (Jeet) Mahal
Mr. Jeetinder Singh (Jeet) Mahal
Chief Operating Officer
Chief Operating Officer
25.37K
+1.44%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Thomas G. (Tom) Wiggans
Mr. Thomas G. (Tom) Wiggans
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
4.73K
-5.40%
Mr. Vishal Kapoor
Mr. Vishal Kapoor
Independent Director
Independent Director
4.38K
--
Dr. Judith Shizuru, M.D., Ph.D.
Dr. Judith Shizuru, M.D., Ph.D.
Director
Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 10月22日 週三
更新時間: 10月22日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Velan Capital Investment Management LP
9.57%
Soleus Capital Management, L.P.
5.36%
Abingworth Management Limited
3.82%
Qiming U.S. Ventures Management, LLC
3.33%
Kingdon Capital Management, L.L.C.
2.74%
其他
75.18%
持股股東
持股股東
佔比
Velan Capital Investment Management LP
9.57%
Soleus Capital Management, L.P.
5.36%
Abingworth Management Limited
3.82%
Qiming U.S. Ventures Management, LLC
3.33%
Kingdon Capital Management, L.L.C.
2.74%
其他
75.18%
股東類型
持股股東
佔比
Hedge Fund
14.98%
Investment Advisor/Hedge Fund
13.98%
Investment Advisor
13.94%
Research Firm
5.41%
Venture Capital
3.92%
Individual Investor
1.05%
Pension Fund
0.07%
其他
46.67%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
196
14.58M
52.29%
-6.24M
2025Q2
200
13.30M
88.50%
-6.79M
2025Q1
208
13.43M
89.40%
-7.30M
2024Q4
197
16.02M
106.64%
-3.08M
2024Q3
183
15.58M
105.01%
-3.10M
2024Q2
159
15.59M
105.21%
-1.23M
2024Q1
125
13.80M
93.49%
+2.29M
2023Q4
104
8.47M
79.62%
-3.17M
2023Q3
105
10.07M
95.42%
-1.18M
2023Q2
146
9.80M
93.27%
-1.97M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Velan Capital Investment Management LP
2.67M
9.57%
+1.23M
+86.10%
Sep 19, 2025
Soleus Capital Management, L.P.
1.49M
5.36%
--
--
Jun 30, 2025
Abingworth Management Limited
1.07M
3.82%
--
--
Jun 30, 2025
Qiming U.S. Ventures Management, LLC
928.96K
3.33%
--
--
Jun 30, 2025
Kingdon Capital Management, L.L.C.
765.00K
2.74%
+80.29K
+11.73%
Jul 03, 2025
Morgan Stanley & Co. LLC
758.02K
2.72%
+117.38K
+18.32%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
703.65K
2.52%
+891.00
+0.13%
Jun 30, 2025
The Vanguard Group, Inc.
624.60K
2.24%
-54.85K
-8.07%
Jun 30, 2025
Integral Health Asset Management, LLC
590.00K
2.12%
+15.00K
+2.61%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
Simplify Propel Opportunities ETF
2.19%
iShares Micro-Cap ETF
0.01%
Vanguard US Momentum Factor ETF
0%
Tema Oncology ETF
0%
Proshares Ultra Russell 2000
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
查看更多
Simplify Propel Opportunities ETF
佔比2.19%
iShares Micro-Cap ETF
佔比0.01%
Vanguard US Momentum Factor ETF
佔比0%
Tema Oncology ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Fidelity Enhanced Small Cap ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
公告日期
類型
比率
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
